Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6331635 | SANOFI AVENTIS US | Taxoids, their preparation and pharmaceutical compositions containing them |
Mar, 2016
(8 years ago) | |
US5847170 | SANOFI AVENTIS US | Taxoids, their preparation and pharmaceutical compositions containing them |
Mar, 2021
(3 years ago) | |
US7241907 | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Dec, 2025
(1 year, 7 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5698582 | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jul, 2012
(11 years ago) | |
US5438072 | SANOFI AVENTIS US | Taxoid-based compositions |
Nov, 2013
(10 years ago) | |
US6372780 | SANOFI AVENTIS US | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
Mar, 2016
(8 years ago) | |
US6387946 | SANOFI AVENTIS US | Methods for treating pathological conditions of abnormal cell proliferation |
Mar, 2016
(8 years ago) | |
US5847170 (Pediatric) | SANOFI AVENTIS US | Taxoids, their preparation and pharmaceutical compositions containing them |
Sep, 2021
(2 years ago) | |
US7241907 (Pediatric) | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Jun, 2026
(2 years from now) | |
US10583110 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
US8927592 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
US10716777 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
US8927592 (Pediatric) | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Apr, 2031
(7 years from now) |
Jevtana Kit is owned by Sanofi Aventis Us.
Jevtana Kit contains Cabazitaxel.
Jevtana Kit has a total of 13 drug patents out of which 7 drug patents have expired.
Expired drug patents of Jevtana Kit are:
Jevtana Kit was authorised for market use on 17 June, 2010.
Jevtana Kit is available in solution;intravenous dosage forms.
Jevtana Kit can be used as increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist, increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist, treatment of cancer, increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist.
Drug patent challenges can be filed against Jevtana Kit from 18 November, 2019.
The generics of Jevtana Kit are possible to be released after 27 April, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-209) | Sep 14, 2020 |
M(M-201) | May 17, 2020 |
M(M-128) | Dec 18, 2023 |
Pediatric Exclusivity(PED) | Nov 17, 2020 |
New Chemical Entity Exclusivity(NCE) | Jun 17, 2015 |
Drugs and Companies using
CABAZITAXEL ingredient